TORNTPHARM
500420Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Torrent Pharmaceuticals Ltd is a leading Indian pharmaceutical company specializing in the research, development, manufacture, and marketing of branded and generic formulations across a wide therapeutic spectrum. The company operates in over 40 countries with a significant presence in the domestic Indian market, and robust operations in advanced markets, including the US, Brazil, and Germany. Torrent Pharma focuses on key segments such as cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infective, and pain management therapies.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating
ESG Rating
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement for completion of dispatch of Postal Ballot Notice
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Notice of Postal Ballot
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of Conference call with Analysts / Investors on Financial Results for the quarter ended 30th June, 2026
Torrent Pharmaceuticals Ltd
About
Torrent Pharmaceuticals Ltd is a leading Indian pharmaceutical company specializing in the research, development, manufacture, and marketing of branded and generic formulations across a wide therapeutic spectrum. The company operates in over 40 countries with a significant presence in the domestic Indian market, and robust operations in advanced markets, including the US, Brazil, and Germany. Torrent Pharma focuses on key segments such as cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infective, and pain management therapies.
The organization is backed by an extensive R&D infrastructure with over 750 scientists and multiple US FDA-approved manufacturing facilities. Guided by a patient-centric approach and regulatory compliance, Torrent continues to enhance its footprint via organic growth and strategic acquisitions.
Business Model & Strategy
Torrent Pharmaceuticals derives its revenues primarily from the sales of branded generics, in-licensed products, and over-the-counter formulations in both domestic and international markets. The company emphasizes specialty therapeutics and has adopted a strategy of focused growth through lifecycle management, portfolio expansion, and geographic diversification. Its growth vectors include new product launches, continuous investments in R&D, strong practitioner relationships, and the scaling up of US generics and differentiated portfolio (including limited-competition and complex generics).
Strategic acquisitions and partnerships have further strengthened its presence in regulated and semi-regulated markets, driving value through integration and operational efficiency.
Management Overview
9 MembersMr.Samir Uttamlal Mehta
Executive Director-Chairperson-CEO-MDSudhirMenon
Chief Financial OfficerMs.Ameera Sushil Shah
Non-Executive - Independent DirectorMs.Nayantara Bali
Non-Executive - Independent DirectorMr.Manish Mahendra Choksi
Non-Executive - Independent DirectorMr.Aman Mehta
Executive DirectorMr.Nikhil Nirvan Khattau
Non-Executive - Independent DirectorMr.Jinal Sudhirbhai Mehta
Non-Executive - Non Independent DirectorMr.Chintan Trivedi
Company Secretary & Compliance OfficerAwards & Recognition
4 Awards- Awarded 'Best Pharma Company in Emerging Markets' at the 2024 India Pharma Awards
- Included in S&P Global Sustainability Yearbook (2024) for ESG initiatives
- ISO 14001 and OHSAS 18001 certifications for environmental and occupational health standards
- Ranked among the Top 10 pharma companies in India by revenue (2024, AIOCD AWACS)
Market Information
Company Timeline
65+ Years of Excellence | 9 Major Milestones
Torrent Pharmaceuticals Ltd founded in Ahmedabad, India
Initial Public Offering (IPO) on BSE
Acquisition of Heumann GmbH, Germany, marking expansion into Europe
Acquisition of Elder Pharma’s domestic formulation business
Set up of new US FDA-approved formulation facility in Dahej, Gujarat
Acquisition of Unichem Laboratories’ branded business for India & Nepal
Launch of Remogliflozin for diabetes under licensing partnership
Commissioning of new manufacturing line at Dahej unit
Recognized for ESG disclosure and sustainability leadership; achieved highest-ever annual revenues
The Next Evolution
Contact Information
Registered Office
Torrent House, Off Ashram Road
Tel: 079-26585090 / 26583060,
Fax: 079-26582100 / (040 - 23420814),
Email: investorservices@torrentpharma.com
Website: torrentpharma.com
Corporate Actions
25| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Final Dividend ₹9 per share | 29 May 2026 Friday | 29 May 2026 Friday | - | - |
Interim Dividend ₹29 per share | 18 Feb 2026 Wednesday | 19 Feb 2026 Thursday | - | - |
Final Dividend ₹6 per share | 20 Jun 2025 Friday | 20 Jun 2025 Friday | - | - |
Interim Dividend ₹26 per share | 31 Jan 2025 Friday | 01 Feb 2025 Saturday | - | - |
Final Dividend ₹6 per share | 21 Jun 2024 Friday | 21 Jun 2024 Friday | - | - |
Interim Dividend ₹22 per share | 12 Feb 2024 Monday | 12 Feb 2024 Monday | - | - |
Final Dividend ₹8 per share | 23 Jun 2023 Friday | 23 Jun 2023 Friday | - | - |
Interim Dividend ₹14 per share | 03 Feb 2023 Friday | 03 Feb 2023 Friday | - | - |
Bonus issue 1:1 | 08 Jul 2022 Friday | 11 Jul 2022 Monday | - | - |
Special Dividend ₹15 per share | 03 Jun 2022 Friday | 06 Jun 2022 Monday | - | - |
Final Dividend ₹8 per share | 03 Jun 2022 Friday | 06 Jun 2022 Monday | - | - |
Interim Dividend ₹25 per share | 02 Feb 2022 Wednesday | 03 Feb 2022 Thursday | - | - |
Final Dividend ₹15 per share | 17 Jun 2021 Thursday | 18 Jun 2021 Friday | - | - |
Interim Dividend ₹20 per share | 15 Feb 2021 Monday | 16 Feb 2021 Tuesday | - | - |
Special Dividend ₹15 per share | 18 Mar 2020 Wednesday | 19 Mar 2020 Thursday | - | - |
Interim Dividend ₹17 per share | 18 Mar 2020 Wednesday | 19 Mar 2020 Thursday | - | - |
Final Dividend ₹4 per share | 13 Jun 2019 Thursday | 14 Jun 2019 Friday | - | - |
Interim Dividend ₹13 per share | 06 Feb 2019 Wednesday | 07 Feb 2019 Thursday | - | - |
Final Dividend ₹5 per share | 18 Jun 2018 Monday | - | 20 Jun 2018 Wednesday | 22 Jun 2018 Friday |
Interim Dividend ₹9 per share | 15 Feb 2018 Thursday | 19 Feb 2018 Monday | - | - |
Final Dividend ₹4 per share | 19 Jun 2017 Monday | - | 21 Jun 2017 Wednesday | 23 Jun 2017 Friday |
Interim Dividend ₹10 per share | 10 Feb 2017 Friday | 13 Feb 2017 Monday | - | - |
Interim Dividend ₹15 per share | 16 Mar 2016 Wednesday | 17 Mar 2016 Thursday | - | - |
Interim Dividend ₹20 per share | 11 Feb 2016 Thursday | 12 Feb 2016 Friday | - | - |
Final Dividend ₹6.25 per share | 15 Jun 2015 Monday | - | 17 Jun 2015 Wednesday | 19 Jun 2015 Friday |
₹1,92,694 Cr.
₹4,949
₹5,250 / 3,481
80.93
₹462.32
10.96
₹62.6
₹5.00
0.75 %
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 7,730 | 8,061 | 8,062 | 8,705 | 9,665 | 10,786 | 11,539 | 13,886 | 15,654 |
| Expenses | - | - | - | 6,811 | 6,874 | 6,536 | 6,994 | 7,818 | 8,522 | 8,842 | 10,925 | 12,677 |
| Profit | - | - | - | 436 | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,911 | 2,138 | 2,156 |
| Tax | - | - | - | 126 | 162 | 274 | 449 | 602 | 696 | 762 | 734 | 711 |
| EPS | - | - | - | 26 | 61 | 74 | 46 | 37 | 49 | 56 | 64 | 14.87 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 14,121 | 14,038 | 14,075 | 13,100 | 15,012 | 15,061 | 14,990 | 44,312 | - |
| Equity And Liabilities | - | - | - | 14,121 | 14,038 | 14,075 | 13,100 | 15,012 | 15,061 | 14,990 | 44,312 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 11 Apr '19 | Mar 2020 29 Apr '20 | Mar 2021 20 Apr '21 | Mar 2022 13 Apr '22 | Mar 2023 17 Apr '23 | Mar 2024 19 Apr '24 | Mar 2025 18 Apr '25 | Mar 2026 17 Apr '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | - | - | - | - | - | - | - | - | - |
| Promoter And Promoter Group | - | - | - | 71.25% | 71.25% | 71.25% | 71.25% | 71.25% | 71.25% | 68.31% | 68.31% | - |
| Non Institutions | - | - | - | 9.61% | 8.08% | 9.03% | 8.14% | 7.71% | 7.36% | 7.03% | 6.45% | - |
| FII | - | - | - | - | - | - | - | 12.04% | 14.14% | 16.31% | 16.18% | - |
| DII | - | - | - | - | - | - | - | 9.00% | 7.26% | 8.35% | 9.06% | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd is a leading Indian pharmaceutical company specializing in the research, development, manufacture, and marketing of branded and generic formulations across a wide therapeutic spectrum. The company operates in over 40 countries with a significant presence in the domestic Indian market, and robust operations in advanced markets, including the US, Brazil, and Germany. Torrent Pharma focuses on key segments such as cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infective, and pain management therapies.
The organization is backed by an extensive R&D infrastructure with over 750 scientists and multiple US FDA-approved manufacturing facilities. Guided by a patient-centric approach and regulatory compliance, Torrent continues to enhance its footprint via organic growth and strategic acquisitions.
Torrent Pharmaceuticals derives its revenues primarily from the sales of branded generics, in-licensed products, and over-the-counter formulations in both domestic and international markets. The company emphasizes specialty therapeutics and has adopted a strategy of focused growth through lifecycle management, portfolio expansion, and geographic diversification. Its growth vectors include new product launches, continuous investments in R&D, strong practitioner relationships, and the scaling up of US generics and differentiated portfolio (including limited-competition and complex generics).
Strategic acquisitions and partnerships have further strengthened its presence in regulated and semi-regulated markets, driving value through integration and operational efficiency.
Awarded 'Best Pharma Company in Emerging Markets' at the 2024 India Pharma Awards
Included in S&P Global Sustainability Yearbook (2024) for ESG initiatives
ISO 14001 and OHSAS 18001 certifications for environmental and occupational health standards
Ranked among the Top 10 pharma companies in India by revenue (2024, AIOCD AWACS)
Torrent Pharmaceuticals Ltd founded in Ahmedabad, India
Initial Public Offering (IPO) on BSE
Acquisition of Heumann GmbH, Germany, marking expansion into Europe
Acquisition of Elder Pharma’s domestic formulation business
Set up of new US FDA-approved formulation facility in Dahej, Gujarat
Acquisition of Unichem Laboratories’ branded business for India & Nepal
Launch of Remogliflozin for diabetes under licensing partnership
Commissioning of new manufacturing line at Dahej unit
Recognized for ESG disclosure and sustainability leadership; achieved highest-ever annual revenues
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon